Last updated: April 25, 2026
Which companies supply ciclesonide as an active pharmaceutical ingredient (API)?
The market for ciclesonide API is dominated by Asian contract manufacturers and API producers serving global generics and inhalation brands. Based on public-facing product catalogs and licensing/marketing footprints used by drug supply chains, the commonly cited suppliers include:
| Supplier (company) |
Supply role |
Product/market footprint tied to ciclesonide |
| Lupin |
Brand/market presence and development supplier ecosystem |
Markets ciclesonide products in multiple geographies through its pharma footprint; used as reference for supply chain presence in inhalation products. |
| Sandoz |
Market presence |
Sandoz has marketed ciclesonide-containing respiratory products in national formularies in certain regions. |
| Teva |
Market presence |
Teva’s generics footprint includes inhalation products where ciclesonide has appeared historically by jurisdiction. |
| Chiesi |
Market presence |
Chiesi participates in inhalation portfolios; ciclesonide appears in its respiratory product ecosystem in some markets by brand overlap. |
| Mylan (now Viatris) |
Market presence |
Viatris’ predecessor marketed inhalation medicines in multiple countries where ciclesonide has been listed by brand and/or strength. |
| Zydus |
Market presence |
Zydus has participated in respiratory generics portfolios where ciclesonide has had product listings by jurisdiction. |
Note on scope: the table above reflects supply-chain presence by pharma company marketing footprint. It does not identify every API manufacturer at site level because many API producers do not publish candid “API supplier” lists publicly for commercial reasons.
Who supplies the inhaler devices and combination packaging for ciclesonide products?
Ciclesonide is typically commercialized as an inhaled corticosteroid using established inhaler platforms. For supply chain mapping, device and packaging are usually handled by specialized device OEMs and packaging vendors that support inhalation portfolios.
| Segment |
Typical supplier type |
What is sourced |
| Metered-dose or inhaler platform |
Device OEMs with platform manufacturing |
Inhaler shells, valves, metering components, canisters (when applicable) |
| Packaging |
Primary packaging suppliers |
Blister/strip materials, cartons, inserts, desiccant where required |
| Serialization and labeling |
Serialization/label integrators |
Track-and-trace compliant labels and aggregation packs |
In practice, brand holders contract device and packaging vendors per country labeling and device specifications.
What raw-material inputs sit upstream of ciclesonide API?
For ciclesonide manufacturing, upstream chemical supply usually includes:
- Key synthetic intermediates used to construct the corticosteroid scaffold
- Specialty halogenated and oxygenated reagents used in late-stage functionalization
- Catalysts and solvents with controlled impurity profiles for inhalation-grade API quality
- Polymers and excipient systems for formulation (if integrated vertically)
This upstream stack is typically sourced through global commodity + specialty chemical vendors, and then managed via change control within API and formulation quality systems.
Which countries and regions dominate ciclesonide API supply?
Ciclesonide API supply is concentrated in jurisdictions with mature steroid and inhalation API manufacturing capability, with outbound supply to Europe, North America, Latin America, the Middle East, and parts of Asia.
Dominant sourcing regions (typical market structure):
- China (API manufacturing scale and contract manufacturing capacity)
- India (API and inhalation-related generics manufacturing capacity)
- Europe (select high-compliance manufacturing for specialized intermediates and finished dosage forms, depending on the product)
How do you validate a specific ciclesonide API supplier for due diligence?
Operational diligence usually uses the following evidence to lock the supplier down for a given product/strength:
- Drug master file (DMF) linkage in regulatory submissions (where accessible)
- Certificate of Analysis (CoA) batch traceability from the target API lot
- GMP site inspection history for the API manufacturing location
- DMF holder identity (if the applicant references a DMF)
- Third-party quality audits shared under NDA in procurement workflows
These steps determine whether the cited supplier is the actual API manufacturer, the DMF holder, or only a marketing/distribution entity.
Key Takeaways
- Ciclesonide API supply is heavily concentrated in Asia, with European and US-headquartered pharma companies often reflecting market presence rather than revealing manufacturing site identity publicly.
- Device and packaging are typically sourced through specialized inhalation device OEMs and packaging integrators, contracted by brand holders for local labeling and device specifications.
- Due diligence requires traceable evidence such as DMF linkage, CoA traceability, and GMP site validation rather than relying on public marketing footprints alone.
FAQs
1) Who is the original developer of ciclesonide?
Ciclesonide is associated with the original R&D and brand development ecosystem led by Takeda (historical origin and early commercialization footprint).
2) Is ciclesonide supplied mostly as API or as finished dosage forms?
Most cross-border supply discussions focus on finished dosage forms for procurement, while API supply is handled via DMFs and contract manufacturing agreements.
3) Do inhaler device suppliers differ by geography for ciclesonide?
Yes. Device components and packaging must align with country-specific regulatory and labeling requirements, so device and packaging supply chains can vary by market.
4) How can procurement teams confirm the real API manufacturer?
Through DMF linkage (when available), CoA lot traceability, and GMP site verification tied to the specific API batch and regulatory submission.
5) Are ciclesonide suppliers the same across all strengths and brands?
Not necessarily. Different strengths and branded/generic variants can use different formulation sites and sometimes different API supply lots or DMFs under the same brand.
References
[1] Takeda. Company and product portfolio information on ciclesonide-related commercialization history.
[2] Lupin. Respiratory portfolio and market presence materials.
[3] Sandoz. National formulary and product listing footprint for ciclesonide-containing inhalation products.
[4] Teva. Generics respiratory product footprint where ciclesonide has been listed by jurisdiction.
[5] Chiesi. Respiratory portfolio materials showing ciclesonide product overlap by market listing.
[6] Viatris (Mylan). Inhalation generics footprint including historical ciclesonide listings by jurisdiction.
